Your session is about to expire
← Back to Search
Melatonin Receptor Agonist
Rozerem + Multi Component Behavior Therapy for Insomnia (CBT Trial)
Phase 4
Waitlist Available
Led By Richard R Bootzin, PhD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, post treatment, 3 month follow up
Awards & highlights
Summary
The specific aims of the proposed study are to compare the sleep, daytime functioning, and circadian phase effects of ROZEREMTM (ramelteon/TAK-375) a selective MT1/MT2 melatonin receptor agonist in humans alone and in combination with multi-component behavior therapy (MCBT) in patients with chronic insomnia.
Eligible Conditions
- Insomnia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, post treatment, 3 month follow up
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, post treatment, 3 month follow up
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Sleep Onset Latency
Secondary study objectives
Dim Light Melatonin Onset
Trial Design
3Treatment groups
Active Control
Placebo Group
Group I: Rozerem + Multi Component Behavior TherapyActive Control1 Intervention
Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
Group II: RozeremActive Control1 Intervention
Rozerem 8mg
Group III: PlaceboPlacebo Group1 Intervention
Placebo pills prepared by Takeda Pharmaceutical.
Find a Location
Who is running the clinical trial?
University of ArizonaLead Sponsor
525 Previous Clinical Trials
155,218 Total Patients Enrolled
4 Trials studying Insomnia
198 Patients Enrolled for Insomnia
University of Colorado, DenverOTHER
1,786 Previous Clinical Trials
2,787,578 Total Patients Enrolled
5 Trials studying Insomnia
977 Patients Enrolled for Insomnia
Richard R Bootzin, PhDPrincipal InvestigatorUniversity of Arizona
Share this study with friends
Copy Link
Messenger